BriaCell rises on FDA 'fast track' tag for cancer therapy

Briacell Therapeutics

13/04/2022 15:22

** U.S.-listed shares of drug developer  BCTX.O  rise 2.1%
to $10.11
    ** U.S. FDA grants "fast track" designation to co's lead
candidate, Bria-IMT, for the treatment of metastatic breast
cancer  urn:newsml:reuters.com:*:nGNX4lcRZ5
    ** The tag is intended to speed up development and review of
therapeutics intended to treat serious or life-threatening
conditions
    ** BriaCell is currently testing Bria-IMT, along with
Incyte's  INCY.O  treatments in an early-to-mid stage study in
patients with advanced breast cancer
    ** Stock up ~22% YTD, including session moves

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))